An agentic artificial intelligence (AI) framework may help researchers gain a better understanding of hidden biological information of tumors, according to a study published in Nature Medicine.
“SPARK helps to refine diagnoses, stratify patients more reliably, and make more precise treatment decisions. Particularly in the field of personalized oncology, there is an opportunity to tailor treatments more closely to the individual biological characteristics of a tumor, thereby improving treatment outcomes,” stated senior author Yuri Tolkach, MD, PhD, Senior Physician, Institute of Pathology, University Hospital Cologne and Medical Faculty, University of Cologne.
Study Methods
Investigators created a foundational agentic AI approach, called SPARK (System of Pathology Agents for Research and Knowledge), for autonomously generated biologically driven tumor analysis using complex pathology data and analytical tools. The framework uses language as a universal interface for more efficient interaction with complex data from histopathological images. The investigators also noted that SPARK does not require additional model training or retraining when working with new biological concepts and analytical tools.
They tested the framework on 18 cohorts of patients with five cancer types, including lung adenocarcinoma, lung squamous cell carcinoma, colorectal cancer, breast cancer, and oropharyngeal squamous cell carcinoma. Additionally, the framework was evaluated on more than 5,400 patients with available histopathology images and clinical prognostic and predictive data, as well as on a dataset of 625 patients with well-characterized spatial biology breast cancer.
Key Findings
The SPARK framework produced relevant clinical and biological concepts that were related to known biomarkers, such as patterns of tumor progression and temporal change, and correlated with prognosis and treatment response.
The investigators created a dedicated module for human interaction with SPARK so that researchers can create analytical approaches for assessing pathological data without needing any programming knowledge.
“With SPARK, we aim to transform pathology from a primarily descriptive discipline into a data-driven, predictive science—and thereby make a significant contribution to precision medicine in oncology,” said Reinhard Büttner, MD, Director of the Institute of General Pathology and Pathological Anatomy, University of Cologne.
They noted, however, that further prospective validation is needed to assess the clinical utility of the framework.
DISCLOSURES: SPARK was funded, amongst others, by the former German Federal Ministry of Education and Research (BMFTR) and as part of the DigiPathConnect project under the European Union’s Interreg Euregio Meuse-Rhine program. In addition, data from the National Network for Genomic Medicine in Lung Cancer (nNGM, funded by German Cancer Aid) were used, as was the computing power of the RAMSES supercomputer at the IT Center University of Cologne (ITCC). For full disclosures of the study authors, visit nature.com.
